Cancer Research ROI

Report quantifies the returns from the U.K.’s investments in oncology.

Written byRina Shaikh-Lesko
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NATIONAL CANCER INSTITUTE, BILL BRANSONFor every pound ($1.70) the U.K. invested in cancer research from 1970 to 2009, the country saw a return of 40 pence ($0.68), according to a report published today (June 16) in BMC Medicine. A team led by Jonathan Grant of the nonprofit RAND Europe and King’s College London harnessed previous work investigating the returns on government investments into heart disease and mental health research.

For the present study, Grant’s team looked at the economic returns from cancer research in the U.K. over nearly four decades. It included economic benefits that came from efforts to reduce smoking rates, to expand cervical cancer screening programs, and from the development of breast cancer treatments like tamoxifen.


“Our findings suggest that despite uncertainties, the historical economic returns were substantial and would justify the public and charitable investment made in cancer research,” coauthor Matthew Grant of Brunel University said in a statement. “However, it is important to note that past performance is not an indicator of future performance, and given the observed increase in cancer research investment over the last two decades, greater net health gains would be needed to see similar returns.”

“This study highlights the significant returns that have been realised as a result of the huge generosity of the British public, who in the last 40 years have contributed an astounding £15 billion [$25.5 billion] to cancer research through their taxes and charitable donations," added Harpal Kumar, chief executive of Cancer Research UK.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies